Skip to main content

Table 3 Absolute and percent change from baseline in excess CST to Weeks 2, 4, and 8 (FAS)

From: Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

  ASP8232 ASP8232/ranibizumab Ranibizumab
Baseline
n 32 32 31
Mean (SD) 215.8 (117.9) 191.8 (103.9) 181.6 (105.5)
Week 2
n 31 32 30
Mean (SD) 230.9 (134.3) 62.3 (109.1) 71.5 (85.3)
%CFB 16.3 (39.4) − 69.3 (55.4) − 57.6 (51.9)
Week 4
n 32 32 31
Mean (SD) 223.1 (130.6) 76.7 (115.0) 88.8 (109.0)
%CFB 11.6 (44.1) − 56 (57.0) − 50.2 (64.4)
Week 8
n 32 32 29
Mean (SD) 224.5 (110.1) 64.9 (114.8) 69.4 (118.8)
%CFB 17.7 (57.1) − 55.1 (77.3) − 66.0 (57.0)
  1. CST central subfield thickness, FAS full analysis set, SD standard deviation